Skip to main content
Toggle navigation
Login
Search
Home
Pharmacogenomics (PGx)
Home
Pharmacogenomics (PGx)
Pharmacogenomics (PGx)
Type here to filter the list
E-001 - INVESTIGATION OF THE RELATIONSHIP BETWEEN LEPR GENOTYPE-LEPTIN-GUT MICROBIOTA COMPOSITION IN HEALTHY NON-OBESE KOREAN ADULTS.
Favorite
CT-009 - ADDRESSING THE RACIAL DISPARITY OF ANGIOTENSIN INHIBITOR ASSOCIATED REDUCTION IN HFREF HOSPITALIZATIONS: DISTINGUISHING BETWEEN RACE AND ANCESTRY
Favorite
PT-004 - EVALUATION OF PHARMACOGENOMIC MEDICATION PRESCRIBING PATTERNS IN RURAL VERSUS URBAN SETTINGS.
Favorite
PT-005 - INTEGRATED GENOMICS AND TRANSCRIPTOMICS ANALYSES USING HAPMAP CELL LINES REVEAL NOVEL MODULATORS OF CELLULAR RESPONSE TO CYCLOPHOSPHAMIDE.
Favorite
PT-006 - A GENOME-WIDE DNA METHYLATION ANALYSIS REVEALS DIFFERENT METHYLATION PATTERNS AND MECHANISTIC CLUES OF MEDICATION-RELATED OSTEONECROSIS OF THE JAW.
Favorite
PT-010 - ALCOHOL USE DISORDER PHARMACOGENOMICS: ROLE OF FNDC4 IN HUMAN NEURONAL FUNCTION.
Favorite
PT-013 - CARE TEAM ATTRIBUTES PREDICT LIKELIHOOD OF UTILIZING PHARMACOGENOMIC INFORMATION.
Favorite
PT-021 - DNA METHYLATION PATTERNS OF ARA-C, DAUNORUBICIN, AND ETOPOSIDE PHARMACOKINETIC/PHARMACODYNAMIC GENES ARE ASSOCIATED WITH THE CLINICAL OUTCOMES IN AML.
Favorite
PII-072 - A VALUE PROPOSITION FOR USING PHARMACOGENETIC TESTING IN MENTAL HEALTH CARE
Favorite
PII-073 - ADDRESSING THE RACIAL DISPARITY OF ANGIOTENSIN INHIBITOR ASSOCIATED REDUCTION IN HFREF HOSPITALIZATIONS: DISTINGUISHING BETWEEN RACE AND ANCESTRY
Favorite
PII-074 - BIPOLAR DISORDER GWAS IDENTIFIED A SNP SIGNAL IN THE THSD7A GENE THAT IS ASSOCIATED WITH RESPONSE TO VALPROATE AND LAMOTRIGINE.
Favorite
PII-075 - DNA METHYLTRANSFERASE INHIBITOR SYNERGIZE WITH IMMUNE CHECK POINT INHIBITORS IN THE TREATMENT OF TRIPLE NEGATIVE BREAST CANCER
Favorite
PII-076 - ESTIMATED PREVALENCE OF ACTIONABLE EXPOSURES TO PHARMACOGENETIC SUPPORTIVE CARE MEDICATIONS AMONG PATIENTS WITH GASTROINTESTINAL CANCERS.
Favorite
PII-077 - EVALUATING THE ACCURACY OF PHARMACOGENOTYPE EXTRACTION FROM SOMATIC WHOLE EXOME SEQUENCING
Favorite
PII-078 - EVALUATION OF G6PD ACTIVITY IN ALL OF US
Favorite
PII-079 - IDENTIFYING EPIGENTIC INFLUENCES ON DRUG METABOLISM: MULTI-OMIC ANALYSES IN AFRICAN AMERICAN HEPATOCYTES
Favorite
PII-080 - IN VITRO COMPARATIVE INHIBITORY PROFILES OF SEVERAL CYP2D6 INHIBITORS AND METABOLIC CAPABILITIES OF CYP2D6*1, CYP2D6*2, CYP2D6*10, AND CYP2D6*17 ON TRAMADOL METABOLISM
Favorite
PII-081 - MISS SCORES VARY IN ACCORDANCE WITH SLCO1B1 STATUS IN A COHORT OF JIA PATIENTS
Favorite
PII-082 - PERSPECTIVES ABOUT THE DEVELOPMENT AND IMPLEMENTATION OF PHARMACOGENOMIC CLINICAL DECISION SUPPORT TOOLS IN RURAL AND UNDERSERVED COMMUNITIES
Favorite
PII-083 - PHARMACOGENOMIC ANALYSIS OF THE PHARMACOKINETIC ENDPOINTS FROM A DRUG-DRUG INTERACTION STUDY OF ENCORAFENIB IN COMBINATION WITH BINIMETINIB USING THE INJE COCKTAIL IN CANCER PATIENTS.
Favorite
PII-084 - PHARMACOGENOMICS OF DILATED CARDIOMYOPATHY: A GENETIC DETERMINANT OF MYOCARDIAL RECOVERY
Favorite
PII-085 - POTENTIAL HEALTHCARE DISPARITIES AMONG PATIENTS WHO REGISTER FOR NOVEL PHARMACOGENETICS CONSULTATION SERVICE
Favorite
PII-086 - RACIAL DIFFERENCES IN THE ASSOCIATION BETWEEN UGT1A1*28 AND GENE EXPRESSION OF UGT1A1 AND SEARCHING FOR NOVEL REGULATORY VARIANTS OF UGT1A1.
Favorite
PII-087 - REDUCTION OF NEXT-GENERATION SEQUENCING FILE SIZE FOR EFFICIENT PHARMACOGENOTYPE EXTRACTION.
Favorite
PII-088 - RISK DETERMINANTS FOR DRUG-INDUCED LIVER INJURY WITH COMMON ANTIBIOTICS IN THE ALL OF US RESEARCH PROGRAM
Favorite
PII-089 - STEREOSELECTIVE METABOLISM OF TRIHEXYPHENIDYL: THE PATHWAY TO PRECISION DOSING
Favorite
OAII-001 - EVALUATION OF PHARMACOGENOMIC MEDICATION PRESCRIBING PATTERNS IN RURAL VERSUS URBAN SETTINGS.
Favorite
OAII-002 - ALCOHOL USE DISORDER PHARMACOGENOMICS: ROLE OF FNDC4 IN HUMAN NEURONAL FUNCTION.
Favorite
OAII-004 - CARE TEAM ATTRIBUTES PREDICT LIKELIHOOD OF UTILIZING PHARMACOGENOMIC INFORMATION.
Favorite
